Gastric damage induced by subchronic administration of preferential cyclooxygenase-1 and cyclooxygenase-2 inhibitors in rats

Pharmacology

Volumn 66, Issue 2, 2002, Pages 68-75

  Villegas, Isabel ^a   Alarcón De La Lastra, Catalina ^a   Martín, M José ^a   Motilva, Virginia ^a   La Casa García, Carmen ^a  

^a UNIVERSITY OF SEVILLE   (Spain)

Author keywords

COX 2 inhibitor; Gastric mucosal injury; Meloxicam; Neutrophil; Piroxicam

Indexed keywords

ASPARTATE AMINOTRANSFERASE; CREATININE; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; MELOXICAM; MYELOPEROXIDASE; NONSTEROID ANTIINFLAMMATORY AGENT; OXICAM DERIVATIVE; PIROXICAM; UREA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLEEDING; CELL ASSAY; CONTROLLED STUDY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG POTENCY; ENZYME ACTIVITY; ENZYME ASSAY; FEMALE; HEMATOLOGICAL PARAMETERS; LIVER; MALE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; RAT; RENAL SYSTEM PARAMETERS; STOMACH EROSION; STOMACH INJURY; THROMBOCYTE; UREMIA;

ANIMALS; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; GASTRIC MUCOSA; GASTROINTESTINAL HEMORRHAGE; ISOENZYMES; MALE; MEMBRANE PROTEINS; PIROXICAM; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RATS; RATS, WISTAR; THIAZINES; THIAZOLES;

EID: 0036037525     PISSN: 00317012     EISSN: None     Source Type: Journal    
DOI: 10.1159/000065628     Document Type: Article

References (42)

1. Role of oxygen radical and lipid peroxidation in indomethacin-induced gastric mucosal injury
2. Effects of food intake and oxidative stress on intestinal lesions caused by meloxicam and piroxicam in rats
3. Mechanism of action of nonsteroidal anti-inflammatory drugs
4. Review article: Cyclo-oxygenase-2: Pharmacology, physiology, biochemistry and relevance to NSAID therapy
5. Distribution and expression of cyclooxygenase (COX) isoenzymes, their physiological roles, and the categorization of nonsteroidal anti-inflammatory drugs
6. Cyclooxygenase-2-selective inhibitors impair glomerulogenesis and renal cortical development
7. Cyclooxygenase-1 and an alternatively spliced mRNA in the rat stomach: Effects of aging and ulcers
8. Constitutive expression of cyclooxygenase-2 in rat vas deferens
9. Multiple female reproductive failures in cyclooxygenase 2-deficient mice
10. Prostaglandins and cyclooxygenases in the spinal cord
11. Alzheimer's disease and inflammation: A review of cellular and therapeutic mechanisms
12. COX-2 inhibitors
13. The advent of highly selective inhibitors of cyclooxygenase - A review
14. Gastrointestinal safety profile of meloxicam: A meta-analysis and systematic review of randomized controlled trials
15. Effects of meloxicam on oxygen radical generation in rat gastric mucosa
16. Role of endogenous sulphydryls and neutrophil infiltration in the pathogenesis of gastric mucosal injury induced by piroxicam in rats
17. Endoscopy of the gastroduodenal mucosa after carprofen, meloxicam, and ketoprofen administration in dogs
18. Review of clinical trials and benefit/risk ratio of meloxicam
19. Assessment of leukocyte in involvement during ischemia and reperfusion on the intestine
20. Adaptation of rat gastric mucosa to aspirin requires mucosal contact
21. Role of gastric blood flow and mucosal cell proliferation in gastric adaptation to aspirin in rat
22. Mucosal adaptation to indomethacin-induced gastric damage in man. Studies on morphology, blood flow and prostaglandin E metabolism
23. Pathologic basis of mucosal adaptation to topical injury
24. Nottingham GI Trials Service for the International SELECT Study Group: Low gastrointestinal toxicity of meloxicam, a preferential inhibitor of the inducible cyclooxygenase (COX-2) enzyme compared to piroxicam
25. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis
26. Gastrointestinal toxicity with celecoxib vs. nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS Study: A randomized controlled trial. Celecoxib long-term arthritis safety study
27. Improvement in gastrointestinal tolerability of the selective cyclooxygenase (COX)-2 inhibitor, meloxicam, compared with piroxicam: Results of the Safety and Efficacy Large-Scale Evaluation of COX-Inhibiting Therapies (SELECT) trial in osteoarthritis
28. Gastrointestinal damage induced by celecoxib and rofecoxib in rats
29. Exacerbation of inflammation-associated colonic injury in rat through inhibition of cyclooxygenase-2
30. Selective cyclooxygenase-2 inhibitors and their influence on the protective effect of a mild irritant in the rat stomach
31. NSAID-induced gastric damage in rats: Requirement for inhibition of both cyclooxygenase 1 and 2
32. Effects of inhibition of prostaglandin endoperoxide synthase-2 in chronic gastrointestinal ulcer models in rats
33. Role of cyclooxygenase-2 in the healing of gastric ulcers in rats
34. Cyclooxygenase 2-implications on maintenance of gastric mucosal integrity and ulcer healing: Controversial issues and perspectives
35. Induction of cyclooxygenase 2 in gastric mucosal lesions and its inhibition by the specific antagonist delays healing in mice
36. Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: Insight into mechanisms and implications for cancer growth and ulcer healing
37. Nonsteroid drug selectivities for cyclooxygenase-1 rather than cyclooxygenase-2 are associated with human gastrointestinal toxicity: A full in vitro analysis
38. Inhibition of both COX-1 and COX-2 is required for development of gastric damage in response to nonsteroidal antiinflammatory drugs
39. Role of vascular mechanisms involved in the acute gastric mucosal injury induced by droxicam and piroxicam in rats
40. Effects of oxicam inhibitors of cyclooxygenase on oxidative stress generation in not gastric mucosa. A comparative study
41. General pharmacology of meloxicam. I. Effects on CNS, gastric emptying, intestinal transport, water, electrolyte and creatinine excretion
42. Bioquímica hepática anormal